Transgenomic Closes $2.2M Private Placement, Inks Preferred Stock Conversion Deal | GenomeWeb

NEW YORK (GenomeWeb) – Transgenomic said today that it has raised $2.2 million through the private placement of preferred stock and warrants with existing investors Crede Capital Group and Third Security.

Separately, the molecular diagnostics firm announced that it has signed an agreement with holders of its outstanding Series A and Series B convertible preferred stock to convert the securities into common stock.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.

Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.

In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.

Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.